Clinical trials: Viral Hepatitis C
Chronic Hepatitis C, Genotype 1 or 4
Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium
The interferon-free combination regimen of ombitasvir/paritaprevir/ritonavir/ with or without dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV) for the treatment of chronic hepatitis C (CHC) has been shown to be safe and effective in…
- Trial name
- NCT02581163
- Testing
- Ombitasvir/paritaprevir/ritonavir, Dasabuvir, Ribavirin
- Volunteers
- 314 people
- Sponsor
- AbbVie
Hepatitis C
Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3
This study is to evaluate the safety, tolerability, and antiviral efficacy of sofosbuvir (SOF) in combination with peginterferon alfa 2a (PEG) and ribavirin (RBV) administered for 12 weeks in participants with chronic genotype 2…
- Trial name
- NCT01808248
- Testing
- SOF, PEG, RBV
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis C
Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C
Compare the effectiveness of telaprevir (VX-950) in combination with Pegylated Interferon Alfa 2a (Peg-IFN-alfa-2a) with and without Ribavirin (RBV) in reducing plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels
- Trial name
- NCT00372385
- Testing
- Ribavirin, Pegylated Interferon Alfa 2a, Telaprevir
- Where
- 4 sites in Austria, France and 2 more
- Volunteers
- 334 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Chronic Hepatitis C
Efficacy and Safety Study of Peginterferon Alfa-2b in Chinese Chronic Hepatitis C Patients
The purpose of this study is to evaluate the efficacy and safety of Peginterferon alfa-2b (40KD, Y shape, the followings will refer as Ypeginterferon alfa-2b for short), at a dose of 180μg/week, in combination with Ribavirin in…
- Trial name
- NCT01581398
- Testing
- Ypeginterferon alfa-2b, Pegasys
- Where
- 42 sites in China
- Volunteers
- 770 people
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Hepatitis C
A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)
The PROVE3 trial is a partially double blinded, randomized, Phase 2 research study of an investigational drug, Telaprevir (VX-950) or Placebo, with Pegylated Interferon Alfa 2a (Peg-IFN-alfa-2a, Pegasys®), and Ribavirin (RBV…
- Trial name
- NCT00420784
- Testing
- Telaprevir, Ribavirin, Pegylated Interferon Alfa 2a
- Where
- 53 sites in United States, Canada and 3 more
- Volunteers
- 465 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Hepatitis C
Tool to Improve Treatment Adherence and Outcomes at Grady Liver Clinic
The purpose of this study is to learn more about what psychological and social factors affect people in how they take their hepatitis C medications.
- Trial name
- NCT03831555
- Testing
- PREP-C
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Emory University
Hepatitis C, Lung Transplant
Expanding the Pool in Lung Transplantation
To perform a study (20 patients) utilizing Hepatitis C positive (HCV Ab+/NAT -) donor lungs for hepatitis C negative recipients with post-operative surveillance and treatment only if a recipient infection occurs.
- Trial name
- NCT03377478
- Testing
- Epclusa
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Pablo Sanchez
Chronic Hepatitis C
Hepatitis C Treatment of Inmates
Hepatitis C infection is a prevalent chronic disease. It is particularly prevalent among intravenous drug abusers. Bergen fengsel is a regional prison housing 250 inmates, of which as many as 70 are recorded HCV RNA PCR positive…
- Trial name
- PEGPRI (NCT00209898)
- Testing
- Fast initiation procedure
- Where
- Norway
- Volunteers
- 42 people
- Sponsor
- Haukeland University Hospital
Chronic HCV Infection
Antaitavir Hasophate Capsules Combined With Yiqibuvir Tablets in Treatment Adult Patients With Chronic Hepatitis C
The safety, tolerability and antiviral activity of Antaitavir Hasophate in Combination With Yiqibuvir in treatment-naive and treatment-experienced patients with chronic hepatitis C virus (HCV) infection
- Trial name
- NCT05395416
- Testing
- HEC74647PA+HEC110114
- Where
- 36 sites in China
- Volunteers
- 514 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Hepatitis C, Chronic
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance.
This 2 arm study will assess the efficacy and safety of PEGASYS plus COPEGUS, with or without concomitant pioglitazone, on hepatitis C virus titers in treatment-naive patients with genotype 1 chronic hepatitis C, and insulin…
- Trial name
- NCT00545233
- Testing
- peginterferon alfa-2a [Pegasys], ribavirin [Copegus], Pioglitazone
- Where
- 66 sites in United States, Puerto Rico
- Volunteers
- 155 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic, HIV Infection
Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen
This phase II, multicentric, national pilot trial is designed to estimate the sustained virological response rate (SVR) following a 12 weeks treatment by telaprevir combined with a 48 or 72 weeks treatment by peginterferon and…
- Trial name
- TelapreVIH (NCT01332955)
- Testing
- Telaprevir, pegIFN alfa-2a, Ribavirin
- Where
- France
- Volunteers
- 70 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Hepatitis C, Chronic
A Phase 1a/1b Study of PPI-383 in Healthy Adults and Hepatitis C Patients
PPI-383 is an antiviral agent (an inhibitor of the hepatitis C virus NS5B polymerase) that is being developed as a potential treatment for hepatitis C virus infection.
- Trial name
- NCT01928147
- Testing
- PPI-383
- Where
- 6 sites in Mauritius, United Kingdom
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Presidio Pharmaceuticals, Inc.
Hepatitis C, Liver
Study Investigating Immunological Effects of Treatment for Chronic Hepatitis C Patients.
Aim To evaluate the effects of peginterferon and ribavirin therapy on the immune response in chronic HCV genotype 1,2 or 3 patients before, during and after treatment.
- Conditions
- Hepatitis C, Liver, Immunology, Regulation
- Trial name
- CIRES (NCT00422838)
- Testing
- fine-needle aspiration biopsy
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Foundation for Liver Research
Hepatitis C
INSTI® HCV (Hepatitis C Virus) Antibody Self-Test Contrived Result Interpretation
The purpose of this Interpretation Assessment was to document if "lay" people, non-professional and inexperienced in self-testing, were able to successfully perform the steps to use a Hepatitis C Virus (HCV) Self-Test (HCVST)…
- Trial name
- NCT06357819
- Testing
- INSTI HCV Self Test
- Where
- Canada
- Volunteers
- 405 people, healthy volunteers welcome
- Sponsor
- bioLytical Laboratories
Human Immunodeficiency Virus, Chronic Hepatitis C
Interactions of Hepatitis C Viral (HCV) Dynamics and Immune Activation in HIV Coinfected Patients During HCV Treatment
The purpose of this study is to investigate T-cell mediated immune responses to HIV-1 and HCV and determine how these responses are affected by HCV treatment and correlates to response.
- Trial name
- DICO (NCT00909129)
- Testing
- pegylated interferon-alpha (Pegasys), ribavirin (COPEGUS)
- Where
- Sweden
- Volunteers
- 25 people
- Sponsor
- Karolinska Institutet
Hepatitis C, Chronic
Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05685AM2)(COMPLETED)
Based on previous experience with peginterferon alfa-2b/ribavirin in combination with boceprevir, the combination with peginterferon alfa- 2a/ribavirin and boceprevir is expected to be safe and well tolerated.
- Trial name
- NCT00845065
- Testing
- Boceprevir, Peginterferon alfa-2a, Ribavirin
- Volunteers
- 202 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV (Human Immunodeficiency Virus), Hepatitis C
Testing of a Navigation Intervention for Hepatitis C and HIV
This study will evaluate the efficacy of navigation for hepatitis C treatment in people living with both HIV and HCV with criminal justice involvement.
- Trial name
- LINKHCV (NCT04499651)
- Testing
- Navigation
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Hepatitis C, Chronic, HIV Infections
Low Dose Peginterferon-α 2a for Chronic Hepatitis C, Genotypes 2 or 3, in HIV-coinfected Patients
Hypothesis: A regimen of low dose of peginterferon alfa-2a plus ribavirin may be as effective as currently recommended regimen for chronic hepatitis C in HIV-coinfected patients.
- Trial name
- SAEI_IFN_1 (NCT00553930)
- Testing
- Pegylated interferon alfa-2a and Ribavirin, Pegylated interferon alfa 2a and Ribavirin
- Where
- Spain
- Volunteers
- 71 people
- Sponsor
- Sociedad Andaluza de Enfermedades Infecciosas
Chronic Hepatitis C
First in Human Study of AL-335; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1
This randomized, double-blind, placebo-controlled, 3-part study will assess the safety, tolerability, and pharmacokinetics of orally administered AL-335 in healthy volunteers (HV) and subjects with CHC infection.
- Trial name
- NCT02339207
- Testing
- AL-335
- Where
- 3 sites in France, Georgia and 1 more
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Alios Biopharma Inc.
Hepatitis C, Chronic Kidney Disease
Effect of Harvoni on Proteinuria and eGFR in Hepatitis C Virus Associated Chronic Kidney Disease (CKD)
Treatment protocol to see if people with hepatitis C (HCV) and chronic kidney disease (CKD) who are treated with Harvoni for 12 weeks have improvements in their kidney disease.
- Trial name
- NCT02503735
- Testing
- Sofosbuvir/Ledipasvir FDC
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Massachusetts General Hospital